PAI-1

Choose Selective PAI-1 Inhibitors

PAI-1 Products

  • All (6)
  • PAI-1 Inhibitors (6)
  • New PAI-1 Products
Catalog No. Product Name Information Product Use Citations Product Validations
S3242 Loureirin B Loureirin B (LB, LrB), a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of PAI-1 with IC50 of 26.10 μM. Loureirin B downregulates p-ERK and p-JNK in TGF-β1-stimulated fibroblasts. Loureirin B promotes insulin secretion mainly through increasing Pdx-1, MafA, intracellular ATP level, inhibiting the KATP current, influx of Ca2+ to the intracellular.
S3785 Notoginsenoside R1 Notoginsenoside R1 (Sanchinoside R1) is the main ingredient with cardiovascular activity in Panax notoginseng. It inhibits TNF-α-induced PAI-1 overexpression via extracellular signal-related kinases (ERK1/2) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling pathways.
J Ethnopharmacol, 2021, S0378-8741(21)00169-0
S6776 TM5275 Sodium TM 5275 sodium is an orally bioavailable plasminogen activator inhibitor-1 (PAI-1) inhibitor with IC50 of 6.95 μM..
S6778 TM5441 TM5441 is an orally bioavailable inhibitor of plasminogen activator inhibitor-1 (PAI-1) with IC50 ranging between 9.7 μM and 60.3 μM. TM5441 induces intrinsic apoptosis in several human cancer cell lines.
S7922 Tiplaxtinin (PAI-039) Tiplaxtinin(PAI-039) is an orally efficacious and selective plasminogen activator inhibitor-1 (PAI-1) inhibitor with IC50 of 2.7 μM.
Cell Chem Biol, 2021, S2451-9456(21)00213-0
Sci Rep, 2021, 11(1):8535
Int J Oncol, 2021, 59(2)59
S9194 Toddalolactone Toddalolactone, a natural coumarin, inhibits the activity of recombinant human Plasminogen activator inhibitor-1 (PAI-1) in a dose-dependent manner, yielding an IC50 value of 37.31 ± 3.23 μM.
S3242 Loureirin B Loureirin B (LB, LrB), a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of PAI-1 with IC50 of 26.10 μM. Loureirin B downregulates p-ERK and p-JNK in TGF-β1-stimulated fibroblasts. Loureirin B promotes insulin secretion mainly through increasing Pdx-1, MafA, intracellular ATP level, inhibiting the KATP current, influx of Ca2+ to the intracellular.
S3785 Notoginsenoside R1 Notoginsenoside R1 (Sanchinoside R1) is the main ingredient with cardiovascular activity in Panax notoginseng. It inhibits TNF-α-induced PAI-1 overexpression via extracellular signal-related kinases (ERK1/2) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling pathways.
J Ethnopharmacol, 2021, S0378-8741(21)00169-0
S6776 TM5275 Sodium TM 5275 sodium is an orally bioavailable plasminogen activator inhibitor-1 (PAI-1) inhibitor with IC50 of 6.95 μM..
S6778 TM5441 TM5441 is an orally bioavailable inhibitor of plasminogen activator inhibitor-1 (PAI-1) with IC50 ranging between 9.7 μM and 60.3 μM. TM5441 induces intrinsic apoptosis in several human cancer cell lines.
S7922 Tiplaxtinin (PAI-039) Tiplaxtinin(PAI-039) is an orally efficacious and selective plasminogen activator inhibitor-1 (PAI-1) inhibitor with IC50 of 2.7 μM.
Cell Chem Biol, 2021, S2451-9456(21)00213-0
Sci Rep, 2021, 11(1):8535
Int J Oncol, 2021, 59(2)59
S9194 Toddalolactone Toddalolactone, a natural coumarin, inhibits the activity of recombinant human Plasminogen activator inhibitor-1 (PAI-1) in a dose-dependent manner, yielding an IC50 value of 37.31 ± 3.23 μM.